Secondary Transactions for Healthcare Private Equity
Written in collaboration with PJT Park Hill, in this white paper, we cover:
Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
Dren Bio, Inc. (“Dren Bio” or the “Company”), a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, today announced that it has entered into a strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). The collaboration will focus on the discovery and development of […]
Artiva Shares Jump 30% After Upsized $167 Million US IPO
Artiva Biotherapeutics Inc. shares pared initial gains to end flat in the company’s trading debut after raising $167 million in an expanded initial public offering. Shares of the clinical stage biotechnology company, backed by South Korea’s Green Cross Corp., traded as high as $16 each before retreating to their $12 IPO price on Friday in New York.
Arcadia Acquires CareJourney to Enable High-performing Networks and Value-based Care Success
Arcadia® (arcadia.io), a leading data platform for healthcare, announced today the acquisition of CareJourney®, a preeminent provider of clinically relevant healthcare data and AI-powered analytics and insights. This strategic acquisition blends Arcadia’s next-generation healthcare data platform, proprietary analytics, and workflow tools with CareJourney’s cost, quality, and benchmark data. CareJourney derives market-leading analytics from Medicare, Medicaid, […]
Providence Medical wins FDA nod for Corus navigation system with Medtronic StealthStation
Providence Medical Technology announced today that the FDA cleared the use of its Corus navigation access system for use in spinal surgery. Pleasanton, California-based Providence’s system provides navigation for its Corus Spinal System during spinal surgery. The company designed it to specifically work with the Medtronic StealthStation for posterior spinal fusion procedures.
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced positive updated safety and efficacy data from its first-in-human study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or […]
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial that demonstrate the company’s lead investigational candidate, ENV-101, improved lung function and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF) […]
Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines
Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument.
Secondary Spotlight ‘The most important letters in PE are D-P-I’: Gerald Cooper on the 2024 Secondary Market Landscape Revelation Partners caught up with Gerald Cooper, Head of the North America Secondary Advisory Practice at Campbell Lutyens, to discuss the 2024 fundraising and exit environment, the evolution of the GP-led secondary market, and considerations for GPs […]
VC Secondary Market Partner Perspectives: Mike Boggs
In this fifth (and final) release in a series of interviews with successful figures in the venture capital secondary market, Derek Minno talks with Mike Boggs, a co-founder of Revelation Partners, which manages over $1.5 billion, making the firm the largest dedicated provider targeting healthcare secondaries. This article features Derek’s takeaways from the conversation along […]